Skip to main content
. 2020 Feb 26;8(2):e16266. doi: 10.2196/16266

Table 2.

Changes in efficacy outcomes between control and intervention groups at 3 months.

Outcomes Mean change from baseline Adjusted mean difference to controla, mean (95% CI) P valuea P value for interaction (intervention x time)b

Control group (n=94), mean (95% CI) Intervention group (n=145), mean (95% CI)


Glycemic parameters

HbA1cc (%) −0.28 (−0.42 to −0.13) −0.63 (−0.77 to −0.50) −0.30 (−0.50 to −0.11) .003d .001d

HbA1c (mmol/mol) −3.02 (−4.62 to −1.42) −6.93 (−8.38 to −5.48) −3.32 (−5.50 to −1.15) .003d .001d

FPGe (mg/dL) −2.41(−13.64 to 8.82) −19.11 (−29.80 to −8.43) −17.29 (−29.33 to −5.26) .005d .02d
Other metabolic parameters

Weight (kg) −0.88 (−2.65 to 0.90) −0.63 (−1.02 to −0.24) 0.22 (−1.26 to 1.71) .77 .35

WCf (cm) −0.88 (−1.61 to −0.16) −0.93 (−1.46 to −0.40) 0.30 (−0.62 to 1.22) .52 .76

BMI (kg/m2) −0.41 (−1.21 to 0.40) −0.26 (−0.40 to −0.11) 0.09 (−0.48 to 0.65) .77 .34

Systolic BPg (mmHg) 3.55 (1.30 to 5.81) −0.20 (−2.30 to 1.90) −3.66 (−6.57 to −0.76) .01d .003d

Diastolic BP (mmHg) 0.68 (−0.94 to 2.30) −2.02 (−3.47 to −0.57) −2.77 (−4.92 to −0.62) .01d .08

Total cholesterol (mg/dL) −2.77 (−8.01 to 2.48) −3.06 (−6.73 to 0.60) −3.81 (−10.04 to 2.42) .23 .35

Triglyceride (mg/dL) −16.88 (−30.14 to −3.62) −16.72 (−31.36 to −2.08) −8.27 (−25.89 to 11.27) .38 .73

HDLh cholesterol (mg/dL) 0.24 (−1.35 to 1.84) 2.44 (1.16 to 3.73) 1.40 (−0.45 to 3.39) .15 .20

LDLi cholesterol (mg/dL) −0.16 (−4.60 to 4.28) −2.99 (−6.03 to 0.04) −4.46 (−9.62 to 0.69) .09 .10
Questionnairesj





DTSQsk 0.45 (−1.03 to 1.92) 2.40 (1.22 to 3.58) 2.21 (0.54 to 3.88) .01d .04d

MMAS-6l 0.06 (−0.15 to 0.28) 0.52 (0.31 to 0.74) 0.31 (0.05 to 0.57) .02d .02d


Motivation 0.04 (−0.11 to 0.20) 0.39 (0.23 to 0.54) 0.23 (0.03 to 0.42) .02d .01d


Knowledge 0.02 (−0.13 to 0.17) 0.14 (0.00 to 0.28) 0.12 (−0.03 to 0.28) .12 .08

aAssessed using the analysis of covariance model with a fixed effect for intervention, and age and respective baseline value as covariates to calculate a least-squares estimate of the treatment difference.

bAssessed using the linear mixed model with fixed effects for age, sex, intervention, time (baseline and 3 months), respective baseline value, baseline value-by time interaction, intervention-by time interaction, and random effects with cluster (centers) and each participant.

cHbA1c: hemoglobin A1c.

dP<.05.

eFPG: fasting plasma glucose.

fWC: waist circumference.

gBP: blood pressure.

hHDL: high-density lipoprotein.

iLDL: low-density lipoprotein

jHigher DTSQs and MMAS-6 scores indicate a favorable state.

kDTSQs: Diabetes Treatment Satisfaction Questionnaire status version.

lMMAS-6: 6-item Morisky Medication Adherence Scale.